Synlogic, Inc. (SYBX) Stock Price & Analysis

Synlogic, Inc. (SYBX) Healthcare & Pipeline Overview

Synlogic, Inc. is a clinical-stage biotechnology firm pioneering synthetic biotic therapeutics for metabolic and immunological disorders. Headquartered in Cambridge, US, the company is advancing a pipeline of orally administered and intratumorally delivered drug candidates, including two in Phase II trials for phenylketonuria, positioning itself in a specialized segment of the biopharmaceutical market.

What Is the Investment Thesis for SYBX?

Synlogic, Inc. presents an investment thesis centered on its innovative synthetic biotic platform and a clinical-stage pipeline targeting rare metabolic and oncology indications. With a market capitalization of $13.0M and a Beta of 0.52, the company exhibits characteristics of a smaller, less volatile biotechnology firm, though its early-stage nature inherently carries higher risk. The advancement of SYNB1618 and SYNB1934 into Phase II clinical trials for phenylketonuria represents a critical value inflection point, as successful progression could validate the platform and attract further investment or partnership opportunities. The company's strategic collaborations with F. Hoffmann-La Roche and Ginkgo Bioworks provide external validation and potential resources for pipeline development. Future growth catalysts are tied to positive clinical trial data readouts, potential expansion into new indications, and the successful navigation of regulatory pathways. However, the inherent risks of clinical trial failures, regulatory hurdles, and the need for significant future funding remain paramount considerations for investors evaluating Synlogic's long-term potential.

Based on FMP financials and quantitative analysis

SYBX Key Highlights

Market capitalization of $13.0M, reflecting its early-stage development and specialized focus within the biotechnology sector.

• Beta of 0.52, indicating lower volatility relative to the broader market, though this can be influenced by its small market cap and clinical stage.
• Pipeline includes two drug candidates, SYNB1618 and SYNB1934, both progressing through Phase II clinical trials for phenylketonuria, a significant milestone for a clinical-stage company.
• Strategic partnerships with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc., enhancing its research and development capabilities.
• Operates with a lean structure, managing 1 employee, which is characteristic of highly specialized, early-stage biopharmaceutical research entities.

Who Are SYBX's Competitors?

SYBX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SYBX's Key Strengths?

Innovative synthetic biotic platform with broad therapeutic potential across metabolic and immunological conditions.

• Advanced clinical pipeline with two drug candidates (SYNB1618, SYNB1934) in Phase II for phenylketonuria.
• Strategic partnerships with major pharmaceutical and biotechnology companies (F. Hoffmann-La Roche, Ginkgo Bioworks).
• Focus on rare diseases and conditions with significant unmet medical needs, potentially offering orphan drug designation benefits.

What Are SYBX's Weaknesses?

Clinical-stage company with no commercialized products, leading to reliance on R&D success and external funding.

• Small market capitalization ($13.0M) and lean operational structure (1 employee) may indicate limited resources compared to larger competitors.
• High capital requirements for ongoing clinical trials and future development, posing potential funding challenges.
• Lack of specific details regarding CEO's background and track record in the provided information.

What Could Drive SYBX Stock Higher?

SYBX catalyst: Positive data readout from Phase II clinical trials for SYNB1618 and SYNB1934 in phenylketonuria, expected to provide crucial validation for the synthetic biotic platform and de-risk these assets.

• Advancement of SYNB1353 for homocystinuria and SYNB8802 for enteric hyperoxaluria through early-stage clinical development, demonstrating pipeline progression and therapeutic breadth.
• Initiation or progression of additional clinical trials for SYNB1891 in solid tumors and lymphoma, further expanding the company's oncology footprint and potential market opportunities.
• Achievement of key milestones or expansion of existing partnerships with F. Hoffmann-La Roche and Ginkgo Bioworks, potentially unlocking additional funding or collaborative research opportunities.

What Are the Key Risks for SYBX?

Financial-distress signal — its Altman Z-Score of -40.50 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-5.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for any of its pipeline candidates (SYNB1618, SYNB1934, SYNB1353, SYNB8802, SYNB1891) could significantly impact the company's valuation and future viability, as it is a clinical-stage entity.
• Regulatory hurdles and the complex approval process for novel synthetic biotic therapeutics, which could lead to delays or outright rejection of drug candidates by health authorities.
• Intense competition within the biotechnology sector from companies developing alternative treatments for metabolic, immunological, and oncology conditions, potentially limiting market share upon commercialization.
• Dependence on external funding and partnerships for continued research and development, with a small market capitalization and lean operational structure suggesting potential vulnerability to capital market fluctuations.

What Are the Growth Opportunities for SYBX?

• **Advancement of Phenylketonuria (PKU) Programs:** The progression of SYNB1618 and SYNB1934 through Phase II clinical trials for phenylketonuria represents a primary growth driver. PKU is a rare genetic metabolic disorder, and successful clinical outcomes could lead to accelerated development pathways and significant market potential within the orphan drug space. The global market for PKU treatments is projected to grow, driven by increased diagnosis and demand for more effective, patient-friendly therapies. Positive Phase II data would de-risk these assets, potentially attracting further investment or licensing opportunities, and moving the company closer to late-stage development and eventual commercialization, potentially within the next 3-5 years.
• **Expansion of Metabolic Disease Pipeline with SYNB1353:** The development of SYNB1353 for homocystinuria offers another significant growth opportunity. Homocystinuria is another rare inherited metabolic disorder with limited treatment options. Bringing SYNB1353 through clinical development could address a critical unmet medical need, expanding Synlogic's footprint in the rare metabolic disease market. Successful preclinical and early clinical data could validate the synthetic biotic platform's versatility across different metabolic pathways, enhancing the company's overall valuation and attracting interest from larger pharmaceutical companies seeking to diversify their rare disease portfolios. The timeline for this opportunity would extend beyond 5 years for commercialization.
• **Progress in Enteric Hyperoxaluria with SYNB8802:** SYNB8802, currently in Phase I trials for enteric hyperoxaluria, targets a condition characterized by excessive oxalate absorption, which can lead to kidney stones and kidney damage. This represents a distinct market opportunity within gastrointestinal and renal health. Advancing this candidate through clinical development could tap into a patient population seeking non-invasive, oral treatment options. Positive early-stage data would support further investment in this program and potentially open doors to broader applications within gut microbiome modulation for various conditions. This program is likely 5+ years from potential commercialization.
• **Oncology Program SYNB1891 for Solid Tumors and Lymphoma:** The development of SYNB1891, an intratumorally delivered synthetic biotic for solid tumors and lymphoma, signifies Synlogic's expansion into the high-value oncology market. This approach leverages the immune-modulating potential of synthetic biotics directly within the tumor microenvironment. Success in Phase I trials and subsequent phases could position SYNB1891 as a novel immunotherapeutic agent, potentially synergistic with existing cancer treatments. The oncology market is vast and continuously seeking innovative therapies, offering substantial revenue potential if clinical milestones are met. This is a long-term growth opportunity, likely 7-10+ years to market.
• **Strategic Partnerships and Collaborations:** Synlogic's existing partnerships with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc. are crucial for its long-term growth. These collaborations provide access to significant financial resources, scientific expertise, and manufacturing capabilities that are vital for a clinical-stage company. Expanding these partnerships, or forming new ones, for specific pipeline assets or platform technologies could accelerate development, reduce financial risk, and provide pathways to global commercialization. Future milestones achieved through these partnerships, such as option exercises or expanded research agreements, represent ongoing value creation opportunities for Synlogic, potentially impacting its financial position within the next 1-3 years.

What Threats Does SYBX Face?

• High risk of clinical trial failures, which could significantly impact company valuation and future prospects.
• Intense competition from other biotechnology and pharmaceutical companies developing treatments for similar conditions.
• Stringent and evolving regulatory hurdles for novel therapeutic modalities like synthetic biotics.
• Reliance on external funding and potential for dilution through equity financing if additional capital is required.
• Intellectual property challenges or expiration of key patents could erode competitive advantage.

What Are SYBX's Competitive Advantages?

• Proprietary Synthetic Biotic Platform: Synlogic's core competitive advantage lies in its unique platform for engineering probiotic bacteria to perform specific therapeutic functions, offering a novel modality for drug development.
• Early-Stage Clinical Pipeline: The company's advanced pipeline, with two candidates in Phase II for PKU, provides a head start in specific therapeutic areas and generates valuable clinical data.
• Strategic Partnerships: Collaborations with F. Hoffmann-La Roche and Ginkgo Bioworks provide access to significant resources, expertise, and potential pathways for development and commercialization, validating its technology.
• Intellectual Property: Development of novel synthetic biotic strains and therapeutic applications is expected to be protected by patents, creating barriers to entry for competitors.
• Focus on Unmet Needs: Targeting rare metabolic diseases and specific oncology indications with limited treatment options allows Synlogic to address high-value markets with less direct competition from established therapies.

What Does SYBX Do?

Synlogic, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and progression of synthetic biotic therapeutics. These innovative treatments are designed to address a range of metabolic and immunological conditions across the United States. The company's strategic focus is on engineering probiotic bacteria to perform specific therapeutic functions within the human body, representing a novel approach in the biopharmaceutical landscape. Synlogic's robust portfolio features several drug candidates, demonstrating a broad therapeutic reach. Key assets include SYNB1618 and SYNB1934, both of which are non-systemically absorbed and orally administered, currently advancing through Phase II clinical trials for the treatment of phenylketonuria (PKU). This represents a significant focus for the company, targeting a rare genetic metabolic disorder. Additionally, Synlogic is developing SYNB1353, another oral, non-systemic agent, specifically designed to treat homocystinuria, further expanding its metabolic disease pipeline. In the realm of gastrointestinal disorders, SYNB8802, an orally taken, non-systemic compound, is presently undergoing Phase I trials for managing enteric hyperoxaluria. Beyond metabolic and gastrointestinal indications, Synlogic is also exploring oncology applications with SYNB1891, an intratumorally delivered synthetic biotic medicine, which is currently under Phase I investigation for solid tumors and lymphoma. The company has strategically forged partnerships with prominent entities such as F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc., which are crucial for research, development, and potential commercialization efforts. Synlogic, Inc. maintains its main office in Cambridge, Massachusetts, a hub for biotechnology innovation, and operates with a lean structure, managing 1 employee.

What Products and Services Does SYBX Offer?

• Develops synthetic biotic therapeutics, which are engineered probiotic bacteria designed to perform specific therapeutic functions.
• Focuses on treating metabolic conditions such as phenylketonuria (PKU) and homocystinuria.
• Also addresses immunological conditions, including solid tumors and lymphoma, with an intratumoral delivery approach.
• Has two drug candidates, SYNB1618 and SYNB1934, in Phase II clinical trials for phenylketonuria.
• Is developing SYNB1353 for homocystinuria and SYNB8802 for enteric hyperoxaluria, both orally administered.
• Explores oncology applications with SYNB1891, an intratumorally delivered synthetic biotic for solid tumors and lymphoma, in Phase I.
• Engages in strategic partnerships with F. Hoffmann-La Roche and Ginkgo Bioworks to advance its pipeline.
• Operates as a clinical-stage biopharmaceutical company, primarily focused on research and development.

How Does SYBX Make Money?

• Primarily relies on research and development activities to advance its pipeline of synthetic biotic therapeutics.
• Seeks to generate future revenue through the successful clinical development, regulatory approval, and commercialization of its drug candidates.
• Leverages strategic partnerships, such as those with F. Hoffmann-La Roche and Ginkgo Bioworks, which may involve upfront payments, milestone payments, and potential royalties on future product sales.
• Currently operates as a pre-revenue company, with its valuation tied to the potential of its intellectual property and clinical pipeline.
• Future revenue streams are anticipated to come from product sales in the United States and potentially other markets, either directly or through licensing agreements.

What Industry Does SYBX Operate In?

Synlogic, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on the emerging field of synthetic biotics. This sector is characterized by intense research and development, long clinical trial timelines, and significant regulatory hurdles. The broader biotechnology market is driven by advancements in genomics, personalized medicine, and novel therapeutic modalities, with a growing emphasis on rare diseases and conditions with unmet medical needs. Synlogic's approach of engineering probiotic bacteria for therapeutic functions positions it within an innovative niche, differentiating it from traditional small molecule or biologic drug developers. The competitive landscape includes other biotechnology firms developing microbiome-based therapies, gene therapies, and enzyme replacement therapies for similar metabolic and immunological conditions. Synlogic's success will depend on its ability to demonstrate superior efficacy and safety profiles for its pipeline candidates, secure intellectual property, and navigate the complex path to market in a capital-intensive industry.

Who Are SYBX's Key Customers?

• Currently, its primary 'customers' are participants in its ongoing clinical trials for various drug candidates.
• In the future, upon regulatory approval, its products would be prescribed by healthcare providers, including specialists in metabolic disorders, gastroenterology, and oncology.
• Ultimate beneficiaries and end-users of its therapeutics would be patients suffering from conditions like phenylketonuria, homocystinuria, enteric hyperoxaluria, solid tumors, and lymphoma.
• Potential partners and licensees from the pharmaceutical industry also represent a crucial 'customer' segment for its platform and pipeline assets.

Company Profile

Synlogic, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Winchester, US. The company is led by CEO Mary Beth Dooley. SYBX has traded publicly since 2015.

Synlogic, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -40.50 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Synlogic, Inc. stands at -5.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.7%, the inverse of the P/E and a quick read on earnings relative to price.

SYBX Valuation & Market Position

With a $13.0M market cap, Synlogic, Inc. sits in the micro-cap segment of the market.

Synlogic, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 49.5% above estimates on average.

Wall Street analysts project Synlogic, Inc. revenue of about $22.8M for fiscal 2026, with EPS near $-0.23.

2 transactions · 1 purchases, 0 sales, 1 other transactions · 1 identified insiders · available records within the last 180 days, newest dated Jul 27, 2026 (coverage not recorded). Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

SYBX Financials

SYBX Latest News

SYBX Analyst Consensus

SYBX MoonshotScore

SYBX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources